3billion published an interview with Sookjin Lee and Chad (ChangDeok) Ji discussing Rare Disease Architecture.
Public source
Publisher name
Public post
𝐖𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐢𝐭 𝐭𝐚𝐤𝐞 𝐭𝐨 𝐬𝐡𝐨𝐫𝐭𝐞𝐧 𝐭𝐡𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐟𝐨𝐫 𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬? Sometimes, the answer goe…
Company
3billion
Your One Answer Genetic testing for rare diseases made more efficient and more accessible
- Industry
- Biotechnology Research
- Location
- Gangnam-gu, KR
- Company size
- 51–200 employees
About 3billion
𝗘𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗢𝗱𝘆𝘀𝘀𝗲𝘆 𝘄𝗶𝘁𝗵 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀. 3billion is dedicated to making rare disease diagnosis faster, more accurate, and accessible for patients everywhere. We provide AI-driven genetic testing covering all rare diseases, helping physicians deliver answers with confidence. Through our unique daily reanalysis system, patients continue to receive new diagnoses without additional cost. 80,000+ patients in 80+ countries have already been tested, in collaboration with 800+ medical institutions worldwide. In 2024, 3billion was listed on KOSDAQ, a recognition of our leading technology and global growth. Our mission is simple yet powerful: to ensure that every rare disease patient has a chance to receive an answer. 🔗 Visit us: https://3billion.io 📩 For inquiries: support@3billion.io
See moreLatest activity
Latest activity from 3billion
6 signals
Presence & Recognition
3billion participated in the 2026 prenatal medical symposium where parents shared the importance of timely diagnoses for newborns.
Presence & Recognition
3billion received parent feedback on Rapid WGS Diagnoses by 3billion at the Prenatal Genetic Counseling Symposium.
Research & Knowledge
3billion reanalysis goes beyond simply repeating the same analysis to revisit existing genomic data and uncover diagnostic insights.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Sano Genetics
Sano Genetics wrote about how the shift from treating rare disease trials as fixed costs of one study to infrastructure across programs and years changes the financial aspect of rare disease development.
Research & Knowledge
AlphaRose Therapeutics
AlphaRose Therapeutics published an article about Everett's family, AlphaRose RareLabs helping, and systemic problems to fix globally to help families like Everett and Rose access genetic technologies.
Research & Knowledge
GeneDx
GeneDx published a study in the journal Genetics in Medicine highlighting the benefits of rapid genome sequencing implemented across pediatric hospital care.
Research & Knowledge
TREAT-NMD
TREAT-NMD published a full article by Dr. Sam Barrell CBE on data fragmentation and funding bottlenecks in rare disease policy, funding, and trial design.
Research & Knowledge
AskBio Inc.